Get started
BioNTech SEBioNTech SEBioNTech SE

BioNTech SE

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

BNTX trade ideas

Great company but highly overrated stock priceBioNTech was a nobody until they made in just one weekend THE mRNA vaccine everyone spoke about for almost a year. They have some big brains out there and they have huge potential but right now, it's just the potential because they aren't really producing the vaccine, Pfizer does it because they have the proper facilities and logistics this vaccine requires. Sorry NASDAQ:BNTX but you need a reality check and I'm sure it will happen after the quarterly report on Monday. $84B company. Like... REALY?! Buckle up!
NASDAQ:BNTXShort
by y01004750
11
BioNTech $BNTX making a breakout from flag patternNASDAQ:BNTX is in a strong uptrend, and last week tested its 50 day MA and its bouncing really good. Today is in focus as the price broke out a continuation pattern with good volume. Also, the MACD is close to make a buy signal with a bullish crossover. BioNTech has a IBD relative strength rating of 97 and is Rank #2 in its industry, just behind NASDAQ:REGN which doesn't have good technicals. With this buy signal I have a target sell on $266.50 with a 2:1 risk/reward ratio.
NASDAQ:BNTXLong
by dpuleo19
In search for the next BNTX, MRNA and NVAX !!Since Covid-19 is here to stay with us with its variants and the vaccines don`t offer lifetime protection, this means that there is room for other companies to develop a better vaccine to address the problem. And the gains in vaccines stock are quite similar to cryptocurrencies year over year. From all time low to all time high, BNTX made 19X, MRNA 24X and NVAX 66X. My question for you is the following: which is the next vaccine developer to make at least 10X our money?? I`m looking forward to discover with you the next big vaccine developer! And i have a presumption or two which i already shared in my group. And those were the fundamentals i was searching for: data submitted to FDA for Emergency Use Authorization, Phase 3, low Market cap - under 1Bil, on the lower end of 52 Week Range, other drugs in the pipeline, high intraday volume.
NASDAQ:BNTXLong
by TopgOptions
18
BioNTech on it's way to new highsPositive Outlook: New ATH Indicators: Neutral to Bullish Trend: overall bullish Stop-Loss: 180 EUR Target: 220 - 240 EUR BioNTech got the approval for it's vaccine (for the use for children at 12 or older) from the EMA end ofMay. This boosted the stock above the resistance at 169 EUR which would break the first range it's trading in. The second, much larger range, was beaten a few days after. It's defined by an inside bar on the daily view. Because of this, a fallback into that range could lead to larger consolidation. Therefore, we put our stop loss just below the last ATH. Target remains in the area between the 38,2 and 61,8 Fib (220 - 240 EUR). Next few days (1-2) will be a little bit of Mid-Consolidation before picking up again. Let's see what happens.
SWB:22UALong
by LGNDRY-Capital
BioNTech could break the wide range upwardNeutral Outlook: Trading in a wide range Indicators: Neutral to Bullish Trend: overall bullish Stop-Loss: 140 EUR Target: 220 - 240 EUR BioNTech will get the approval or denial for it's vaccine (for the use for children at 12 or older) from the EMA today. This could boost the stock above the resistance at 169 EUR which would break the first range it's trading in. The second, much larger range is between the ATH (185 EUR) and 121 EUR. It's defined by an inside bar on the daily view. Considering the approval, the overall market and news flow for vaccines and the cheap valuation of BioNTech I would risk a shot here. Stop-Loss should be below the first range line at 140 EUR. Target is the area between the 38,2 and 61,8 Fib (220 - 240 EUR). Let's see what happens.
SWB:22UALong
by LGNDRY-Capital
Biontech with a target of 225€ for JuneBiontech had a run of 135% from April to May but also tanked up to -35% in a short period of time due to the Biden patent waive statement. Nevertheless, the FUD is over, we are still in a bullish momentum and the fundamentals are looking better than ever. Bear in mind, I'm drawing only charts here, eventhough my bullish forecast is also backed by the earning reports of Pfizer and Biontech itself. I won't post any numbers or calculations. Everyone has to do its own due dilligence. All I can say is, that the stock is undervalued at this prices currently. My long term targets are also higher than 225€. But for now I go with 225€ for early June. I also think that the price will leap up from quarter reports to quarter reports. To the chart: After the big -35% drop we had a real strong buy back, which is showing still a bullish momentum. Currently, we are forming a bullish pennant. If we measure the height of it and project it of a break out, we'll get a target nearby. 225€. The yellow, orange and red wave are messured wave extentions which are all targeting the same price range nearby 225€. We have not many resistances ahead of us currently. There is the last ATH of 185€ and at the same price range, the median line of the parallel channel. Breaking above it, would head us direclty to the upper boundary of the parallel channel at 225€. Risk: Forecasting a price target to a specific date is higly speculative and there is a high likelihood that I will be wrong. The stock price is highly manipulated due to the overall sentiment and external news. Eventhough the fundamentals are bullish, we could have a longer period of sidewards movement. That would change the outcome of the predicted target. Do your own due dilligence!
FWB:22UALong
by MuffyPuffy
3
$BNTX PT 260 and higherCoronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age. The FDA amended the EUA originally issued on Dec. 11, 2020 for administration in individuals 16 years of age and older. “The FDA’s expansion of the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents 12 through 15 years of age is a significant step in the fight against the COVID-19 pandemic,” said Acting FDA Commissioner Janet Woodcock, M.D. “Today’s action allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic. Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations.” From March 1, 2020 through April 30, 2021, approximately 1.5 million COVID-19 cases in individuals 11 to 17 years of age have been reported to the Centers for Disease Control and Prevention (CDC). Children and adolescents generally have a milder COVID-19 disease course as compared to adults. The Pfizer-BioNTech COVID-19 Vaccine is administered as a series of two doses, three weeks apart, the same dosage and dosing regimen for 16 years of age and older. The FDA has determined that Pfizer-BioNTech COVID-19 Vaccine has met the statutory criteria to amend the EUA, and that the known and potential benefits of this vaccine in individuals 12 years of age and older outweigh the known and potential risks, supporting the vaccine’s use in this population. “Having a vaccine authorized for a younger population is a critical step in continuing to lessen the immense public health burden caused by the COVID-19 pandemic,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “With science guiding our evaluation and decision-making process, the FDA can assure the public and medical community that the available data meet our rigorous standards to support the emergency use of this vaccine in the adolescent population 12 years of age and older.” The FDA has updated the Fact Sheets for Healthcare Providers Administering the Vaccine (Vaccination Providers) and for Recipients and Caregivers with information to reflect the use of the vaccine in the adolescent population, including the benefits and risks of the Pfizer-BioNTech COVID-19 Vaccine. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine was issued to Pfizer Inc. The issuance of an EUA is not an FDA approval (licensure) of a vaccine. The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biologics for prevention and treatment of COVID-19 is terminated, and may be revised or revoked if it is determined the EUA no longer meets the statutory criteria for issuance or to protect public health or safety. FDA Evaluation of Available Safety Data The available safety data to support the EUA in adolescents down to 12 years of age, include 2,260 participants ages 12 through 15 years old enrolled in an ongoing randomized, placebo-controlled clinical trial in the United States. Of these, 1,131 adolescent participants received the vaccine and 1,129 received a saline placebo. More than half of the participants were followed for safety for at least two months following the second dose. The most commonly reported side effects in the adolescent clinical trial participants, which typically lasted 1-3 days, were pain at the injection site, tiredness, headache, chills, muscle pain, fever and joint pain. With the exception of pain at the injection site, more adolescents reported these side effects after the second dose than after the first dose, so it is important for vaccination providers and recipients to expect that there may be some side effects after either dose, but even more so after the second dose. The side effects in adolescents were consistent with those reported in clinical trial participants 16 years of age and older. It is important to note that as a general matter, while some individuals experience side effects following any vaccination, not every individual’s experience will be the same and some people may not experience side effects. The Pfizer-BioNTech COVID-19 Vaccine should not be given to anyone with a known history of a severe allergic reaction, including anaphylaxis—to any component of the vaccine. Since its authorization for emergency use, rare severe allergic reactions, including anaphylaxis, have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine in some recipients. FDA Evaluation of Available Effectiveness Data The effectiveness data to support the EUA in adolescents down to 12 years of age is based on immunogenicity and an analysis of COVID-19 cases. The immune response to the vaccine in 190 participants, 12 through 15 years of age, was compared to the immune response of 170 participants, 16 through 25 years of age. In this analysis, the immune response of adolescents was non-inferior to (at least as good as) the immune response of the older participants. An analysis of cases of COVID-19 occurring among participants, 12 through 15 years of age, seven days after the second dose was also conducted. In this analysis, among participants without evidence of prior infection with SARS-CoV-2, no cases of COVID-19 occurred among 1,005 vaccine recipients and 16 cases of COVID-19 occurred among 978 placebo recipients; the vaccine was 100% effective in preventing COVID-19. At this time, there are limited data to address whether the vaccine can prevent transmission of the virus from person to person. In addition, at this time, data are not available to determine how long the vaccine will provide protection. Ongoing Safety Monitoring As part of the original EUA request, Pfizer Inc. submitted a plan to continue monitoring the safety of the vaccine as it is used under EUA. This plan has been updated to include the newly authorized adolescent population, and includes longer-term safety follow-up for participants enrolled in ongoing clinical trials, as well as other activities aimed at monitoring the safety of the Pfizer-BioNTech COVID-19 vaccine and ensuring that any safety concerns are identified and evaluated in a timely manner. It is mandatory for Pfizer Inc. and vaccination providers to report the following to the Vaccine Adverse Event Reporting System for Pfizer-BioNTech COVID-19 Vaccine: all vaccine administration errors, serious adverse events, cases of Multisystem Inflammatory Syndrome and cases of COVID-19 that result in hospitalization or death.
NASDAQ:BNTXLong
by BADQOMOCAWGOWLD
1
$BNTX Ascending Triangle breakout in next 3 days?BNTX has formed an Ascending Triangle indicating breakout in next three days for run to earnings. I've taken some good profits on this since the last earnings, got in at 102, so may be a bit biased. On the other side - this has been a LONG bull run and is clearly overbought already. The ascending triangle would seem to indicate it's got some more bullish energy left though. China is on the verge of approving it in the news... Also in the news watch out if the White House issues an intellectual property waiver on vaccines . This most certainly could have a dramatic effect on the price action.
NASDAQ:BNTXLong
by Thundershadow